Mathematical Modeling to Determine Basic Muscle Properties in the Failing

Status Terminated

Clinical Trial Summary

According to the most recent information released by the American Heart Association, heart failure affects 5.8 million Americans and over 23 million people worldwide. In particular, diastolic heart failure (DHF) has emerged in approximately half of those suffering from heart disease and has become a major public health problem for many reasons, including the complexity of the disease, lack of effective drugs/therapies, requirement of invasive tests to diagnose and monitor DHF, and the absence of a suitable scientific model to study the disease. Scientists and physicians alike still do not fully understand what happens to the muscles in the heart (myocardium) patients who present with diastolic dysfunction or DHF. Therefore, the medical field is in need of an accurate model that can evaluate how diastolic dysfunction leads to heart failure and what happens at a cellular level as this disease emerges and progresses.

Clinical Trial Description

Our group has developed a mathematical model of the heart that gathers data from a procedure called an echocardiograph (echo) to analyze how muscles in the heart are functioning. This model incorporates how the heart muscle functions on a cellular level along with the overall functionality of the heart. We hypothesize that this model will measure the specific properties of the heart muscle that affect their ability to contract and relax. This study will determine whether these properties will be different in patients with DHF compared to healthy controls. We also propose that these abnormalities in the heart muscle will correlate with the patient's degree of heart failure and their prognosis when doctors evaluate using standard clinical tests. This study will be conducted at the University of Nebraska Medical Center (UNMC). 40 subjects will be enrolled, 20 healthy controls with no history of heart disease and 20 subjects who have been diagnosed with diastolic heart failure. Healthy controls will be required to undergo 1 echocardiograph procedure at UNMC. Subjects diagnosed with DHF will be required to undergo 6 echocardiograph procedure over the course of 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01778894
Study type	Observational
Source	University of Nebraska
Contact
Status	Terminated
Phase
Start date	September 1, 2013
Completion date	February 3, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02499601` - CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD)	N/A
Completed	`NCT02537041` - Non-invasive Evaluation of Myocardial Stiffness by Elastography	N/A
Completed	`NCT02275793` - The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
Withdrawn	`NCT00773084` - Aliskiren and Renin Inhibition in Diastolic Heart Failure	N/A
Terminated	`NCT00293150` - Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure	Phase 4
Terminated	`NCT01942395` - Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)	N/A
Recruiting	`NCT03157219` - Manipal Heart Failure Registry (MHFR)	N/A
Completed	`NCT04154878` - 2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).
Recruiting	`NCT01599117` - A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]	Phase 3
Completed	`NCT01185067` - Physiological Effects of Grape Seed Extract in Diastolic Heart Failure	Phase 1
Completed	`NCT03338374` - Cardiac Resynchronisation Therapy Versus Rate-responsive Pacing in Heart Failure With Preserved Ejection Fraction	N/A
Completed	`NCT02589977` - Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF	Phase 4
Completed	`NCT02147613` - High Intensity Interval Exercise in Diastolic Heart Failure	N/A
Terminated	`NCT00083772` - Use of Nesiritide in the Management of Acute Diastolic Heart Failure	Phase 4
Completed	`NCT00303498` - A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure	Phase 2
Terminated	`NCT02254382` - Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure	N/A
Completed	`NCT00839228` - Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome	Phase 2
Terminated	`NCT00662116` - Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)	Phase 2
Completed	`NCT02916225` - High Intensity Interval Training Versus Moderate Continuous Training in Heart Failure With Preserved Ejection Fraction	N/A
Completed	`NCT02084992` - A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Mathematical Modeling to Determine Basic Muscle Properties in the Failing Heart

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms